Estimating economic damages relating to type 2 diabetes drug

Pharma production

A pharmaceutical company brought on a CRA consultant to estimate economic damages arising from alleged infringement and at-risk launch of a patented oral antihyperglycemic drug used in the management of type 2 diabetes. The alleged economic damages were estimated according to appropriateness and, if so, quantum of lost profits, price erosion, and reasonable royalty elements.

Meet our team